Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03407105 · ClinicalTrials.gov registry record · Phase 1
A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03407105 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 24 participants.
The verdict
NCT03407105, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of 2 or 4 doses of MDX-010 in HIV-infected subjects
Interventions
- BIOLOGICAL MDX-010
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2003-04-21 |
| Est. Completion | 2006-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03407105
The ClinicalTrials.gov registry entry for NCT03407105 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MDX-010 is the first listed.
NCT03407105 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03407105 about?
NCT03407105 is a clinical study titled "A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)". The purpose of this study is to assess the safety and tolerability of 2 or 4 doses of MDX-010 in HIV-infected subjects
What is the current status of trial NCT03407105?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2003-04-21. Estimated completion is 2006-02-21.
What interventions are being tested in trial NCT03407105?
The interventions under investigation include: MDX-010 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03407105?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.